Patents by Inventor Jason C. Schense
Jason C. Schense has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140343324Abstract: Biomaterials containing a three-dimensional polymeric network formed from the reaction of a composition containing at least a first synthetic precursor molecule having n nucleophilic groups and a second precursor molecule having m electrophilic groups wherein the sum of n+m is at least five and wherein the sum of the weights of the first and second precursor molecules is in a range from about 8 to about 16% b weight of the composition, preferably from about 10 to about 15%, more preferably from about 12 to about 14.5% by weight of the composition. In one embodiment, the first and second precursor molecules are polyethylene glycols functionalized with nucleophilic and electrophilic groups, respectively. In a preferred embodiment, the nucleophilic groups are amino and/or thiol groups and the electrophilic groups are conjugated, unsaturated groups.Type: ApplicationFiled: May 21, 2014Publication date: November 20, 2014Applicants: Eidgenossische Technische Hochschule Zürich, Universität ZürichInventors: Matthias Lütolf, Jason C. Schense, Anna Jen, Marina Capone, Jeffrey A. Hubbell
-
Patent number: 8309518Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF? superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.Type: GrantFiled: July 28, 2010Date of Patent: November 13, 2012Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jason C. Schense, Hugo Schmoekel, Jeffrey A. Hubbell, Franz Weber
-
Patent number: 8034618Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g.Type: GrantFiled: February 27, 2007Date of Patent: October 11, 2011Assignees: Eldgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Matthias Lutolf, Jason C. Schense, Jeffrey A. Hubbell, Anna Jen
-
Publication number: 20100291215Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF? superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.Type: ApplicationFiled: July 28, 2010Publication date: November 18, 2010Applicants: Eidgenossische Technische Hochschule, UniversitatInventors: Jason C. Schense, Hugo Schmoekel, Jeffrey Alan Hubbell, Franz Weber
-
Patent number: 7601685Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g.Type: GrantFiled: December 17, 2002Date of Patent: October 13, 2009Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama-Elbert
-
Patent number: 7241730Abstract: Heparin-binding regions of several proteins, such as neural cell adhesion molecule, fibronectin, laminin, midkine, and anti-thrombin III have been shown to promote neurite extension on two-dimensional surfaces. The effect of heparin-binding peptides on neurite extension through three-dimensional matrices was investigated by culturing embryonic chick dorsal root ganglia (DRG) within fibrin gels containing chemically attached heparin-binding peptide (HBP). The length of neurites within fibrin gels containing cross-linked HBP was increased by more than 70% over extension through fibrin gels containing no peptide. The HBP sequence of antithrombin III was incorporated into the fibrin gel as the C-terminal domain of a bidomian, chimeric peptide; the N-terminal second domain of this peptide contained the ?2-plasmin inhibitor substrate for Factor XIIIa. Factor XIIIa, a transglutaminase, was used to chemically attach the HBP-containing chimeric peptide to the fibrin gels during polymerization.Type: GrantFiled: March 25, 2002Date of Patent: July 10, 2007Assignees: Universitat Zurich, Eidgenossische Technische Hochschule ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama
-
Patent number: 6960452Abstract: Disclosed are materials that may be used in the design of improved devices and wound treatment platforms though covalent and/or non-covalent attachment of bioactive proteins. The proteins comprise any variety of cell growth and/or healing promoting proteins, such as growth factor. The incorporation of these whole proteins may be designed to provide controlled release thereof in a biological system through further use of enzyme degradation sites. Heparin-binding protein or fusion proteins synthesized to contain a heparin-binding domain are two mechanisms that may be used in providing these properties to a matrix, such as a fibrinogen matrix. The proteins will be used to provide enhanced healing in various tissues including vasculature, skin, nerve, and liver. The materials disclosed will be used to enhance would?? Healing and other generative processes by engineering the fibrin gel to contain appropriate proteins with specifically designed release and/or degradation characteristics.Type: GrantFiled: March 2, 2001Date of Patent: November 1, 2005Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama
-
Patent number: 6894022Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling, and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, enzymatic action, and/or diffusion. In one embodiment, a fusion protein, which contains a crosslinking region, such as a factor XIIIa substrate, and a native protein sequence, such as a bioactive factor, is constructed. Degradable linkages may be included between the crosslinking region and the bioactive factor.Type: GrantFiled: May 1, 2000Date of Patent: May 17, 2005Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama-Elbert
-
Publication number: 20030187232Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g.Type: ApplicationFiled: December 17, 2002Publication date: October 2, 2003Applicant: Eidgenossische Technische Hochschule Zurich Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama-Elbert, Anna Jen
-
Publication number: 20030166833Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g.Type: ApplicationFiled: December 18, 2002Publication date: September 4, 2003Applicant: Eidgenossische Technische Hochschule ZurichInventors: Matthias Lutolf, Jason C. Schense, Jeffrey A. Hubbell, Anna Jen
-
Publication number: 20030119186Abstract: Heparin-binding regions of several proteins, such as neural cell adhesion molecule, fibronectin, laminin, midkine, and anti-thrombin III have been shown to promote neurite extension on two-dimensional surfaces. The effect of heparin-binding peptides on neurite extension through three-dimensional matrices was investigated by culturing embryonic chick dorsal root ganglia (DRG) within fibrin gels containing chemically attached heparin-binding peptide (HBP). The length of neurites within fibrin gels containing cross-linked HBP was increased by more than 70% over extension through fibrin gels containing no peptide. The HBP sequence of antithrombin III was incorporated into the fibrin gel as the C-terminal domain of a bidomain, chimeric peptide; the N-terminal second domain of this peptide contained the &agr;2-plasmin inhibitor substrate for Factor XIIIa. Factor XIIIa, a transglutaminase, was used to chemically attach the HBP-containing chimeric peptide to the fibrin gels during polymerization.Type: ApplicationFiled: March 25, 2002Publication date: June 26, 2003Applicant: Eidgenossische Technische Hochschule ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama
-
Publication number: 20030012818Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF&bgr; superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.Type: ApplicationFiled: April 25, 2002Publication date: January 16, 2003Applicant: Eidgenossische Technische Hochschule Zurich and Universitat ZurichInventors: Jason C. Schense, Hugo Schmoekel, Jeffrey Alan Hubbell, Franz Weber
-
Patent number: 6468731Abstract: Disclosed are materials that may be used in the design of improved devices and wound treatment platforms though covalent and/or non-covalent attachment of bioactive proteins. The proteins comprise any variety of cell growth and/or healing promoting proteins, such as growth factor. The incorporation of these whole proteins may be designed to provide controlled release thereof in a biological system through further use of enzyme degradation sites. Heparin-binding protein or fusion proteins synthesized to contain a heparin binding domain are two mechanisms that may be used in providing these properties to a matrix, such as a fibrinogen matrix. The proteins will be used to provide enhanced healing in various tissues including vasculature, skin, nerve, and liver. The materials disclosed will be used to enhance would healing and other generative processes by engineering the fibrin gel to contain appropriate proteins with specifically designed release and/or degradation characteristics.Type: GrantFiled: September 29, 2000Date of Patent: October 22, 2002Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama
-
Publication number: 20010020086Abstract: Disclosed are materials that may be used in the design of improved devices and wound treatment platforms though covalent and/or non-covalent attachment of bioactive proteins. The proteins comprise any variety of cell growth and/or healing promoting proteins, such as growth factor. The incorporation of these whole proteins may be designed to provide controlled release thereof in a biological system through further use of enzyme degradation sites. Heparin-binding protein or fusion proteins synthesized to contain a heparin-binding domain are two mechanisms that may be used in providing these properties to a matrix, such as a fibrinogen matrix. The proteins will be used to provide enhanced healing in various tissues including vasculature, skin, nerve, and liver. The materials disclosed will be used to enhance would?? Healing and other generative processes by engineering the fibrin gel to contain appropriate proteins with specifically designed release and/or degradation characteristics.Type: ApplicationFiled: March 2, 2001Publication date: September 6, 2001Inventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama